The FDA has granted Spino Modulation (a Spinologics subsidiary) a “Breakthrough Device Designation” for our MIScoli(TM) system
Recent Posts
-
Cervision™ – Premier lancement commercial international au
26 January 2022 -
La modélisation et la simulation
17 November 2021 -
Communiqué de presse Kollide
27 October 2021